Viatris
↗Canonsburg, Pennsylvania, United States
Viatris Inc. is a global pharmaceutical company headquartered in Canonsburg, Pennsylvania, formed through the merger of Mylan and Pfizer's Upjohn division on November 16, 2020. The company operates as a diversified pharmaceutical manufacturer specializing in generic, branded, biosimilar, and over-the-counter medications across more than 165 countries and territories, supplying medicines to approximately 1 billion people annually. With a portfolio of 1,400 approved therapeutic molecules and approximately 32,000 employees, Viatris serves as a major player in the global generics and specialty pharmaceuticals market. The company is transitioning from a legacy generics-focused business to a more innovative portfolio through strategic acquisitions and partnerships, particularly in ophthalmology and innovative therapeutics such as cardiovascular and immunology treatments.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Generics, Specialty Pharma, Biosimilars
SIZE & FINANCIALS
Employees:10000+
Revenue:$14.7B
Founded:2020
Ownership:public
Status:operating
FUNDING
Stage:N/A - Public Company
STOCK
Exchange:NASDAQ
Ticker:VTRS
Market Cap:$14.35B
PIPELINE
Stage:Phase 1 to Commercial
Lead Drug Stage:Phase 3
Modalities:Small molecule, Generic drugs, Branded generics, Biosimilars, Over-the-counter, Active pharmaceutical ingredients, Gene therapy, Injectable
Active Trials:6
Trial Phases:Phase 1: 1 | Phase 3: 6
FDA Approvals:1400
CORPORATE STRUCTURE
Subsidiaries:Mylan Laboratories Limited (India), Aculys Pharma, Inc. (acquired 2024, Japan), Oyster Point Pharma (acquired January 2023), Famy Life Sciences (acquired January 2023)
Key Partnerships:Idorsia - R&D collaboration for selatogrel and cenerimod (2024, $350M upfront), Sandoz - Biosimilar development collaboration, Regeneron - Eylea biosimilar partnership (with patent disputes)
COMPETITION
Position:Leader
Competitors:Teva Pharmaceuticals, Sandoz (Novartis division), Sun Pharmaceutical, Perrigo Company, Hikma Pharmaceuticals, Fresenius Kabi, Lupin Limited, Endo International +3 more
LEADERSHIP
Key Executives:
Scott A. Smith - Chief Executive Officer
Anil Amin - Chief Business Development Officer
Lara Ramsburg - Chief Corporate Affairs Officer
Andrew Enrietti - Chief Administrative and Transformation Officer
Jeff Nau - President, Eye Care Division
William Szablewski - Head of Capital Markets
Board Members:Pauline van der Meer Mohr (Chairperson), Michael Goettler (Board Member (former CEO)), Rajiv Malik (Board Member), Thomas Farley (Board Member)
LINKS
Website:viatris.com
Crunchbase:Crunchbase Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Viatris. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.